A. Educational Background 

  
 

1997 - 2001

Postdoctoral Research Fellow, Lab of Pathology, National Cancer Institute, Nationa Institute of Health

​
 

1993 - 1997

 Ph.D. in Pharmacy, Sung Kyun Kwan University, Seoul, Korea

            College of Pharmacy, Department of Biochemistry and Molecular Biology

 

1989 - 1991

M.S. in Pharmacy, Sung Kyun Kwan University, Seoul, Korea

                      College of Pharmacy, Department of Biochemistry and Molecular Biology

 

1985 - 1989          

 B.S. in Pharmacy, Sung Kyun Kwan University, Seoul, Korea

            College of Pharmacy, Department of Biochemistry and Molecular Biology

​

B. Professional Experience

 

2003.3. - present

Professor, Lab of Pathology, The Catholic University of Korea, Seoul, Korea.

                     
 

2001.9 - 2003.2.

Assistant Professor, Yonsei University, College of Medicine, Seoul, Korea.

 

2001.6 - 2002.8

Visiting Scientist, Microarray & Expression Genomics Laboratory, 

Genome Institute of Singapore, National University of Singapore, Singapore.

 

1997 - 2001

Post-doctoral fellow, Lab of Pathology, National Cancer Institute, 

National Institutes of Health, Bethesda, MD, USA

​

C. Selected recent publications (2010 to present, Corresponding author)

​

2021

SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer.

Kim SY, Shen Q, Son K, Kim HS, Yang HD, Na MJ, Shin E, Yu S, Kang K, You JS, Yu KR, Jeong SM, Lee EK, Ahn YM, Park WS, Nam SW.Oncogene. 2021 Jul;40(28):4652-4662. doi: 10.1038/s41388-021-01875-6. Epub 2021 Jun 17.PMID: 34140644

IF: 9.867

​

2020

 

Characteristic molecular signature of pericardial effucion identifies malignant cancer in pericardial disorder patients

Kim SY, Eun JW, Kim HS, Yang HD, Na MJ, Ahn YM, Jung HO, Nam SW.

Molecular & Cellular Toxicology. 2020.

IF: 1.830

​

2019

​

HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.

Yang HD, Kim HS, Kim SY, Na MJ, Yang G, Eun JW, Wang HJ, Cheong JY, Park WS, Nam SW.

Hepatology. 2019 Apr 16. doi: 10.1002/hep.30657. [Epub ahead of print]

IF: 17.425

​

2017, 2018

​

Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.

Shen Q*, Eun JW*, Lee K*, Kim HS, Yang HD, Kim SY, Lee EK, Kim T, Kang K, Kim S, Min DH, Oh SN, Lee YJ, Moon H, Ro SW, Park WS, Lee JY, Nam SW.

Hepatology. 2018 Apr;67(4):1360-1377. doi: 10.1002/hep.29606.

IF: 17.425

 

MicroRNA-495-3p functions as a tumour suppressor by regulating multiple epigenetic modifiers in gastric carcinogenesis.

Eun JW*, Kim HS*, Shen Q, Yang HD, Kim SY, Yoon JH, Park WS, Lee JY, Nam SW.

J Pathol. 2017 Oct 9. doi: 10.1002/path.4994. [Epub ahead of print]

IF: 7.996

 

2016

 

1. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.

Hong SH*, Eun JW*, Choi SK, Shen Q, Choi WS, Han JW, Nam SW, You JS.

Oncotarget. 2016 Apr 12. doi: 10.18632/oncotarget.8701. [Epub ahead of print]

IF: 6.359

 

2. Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer.

Yang HD*, Kim PJ*, Eun JW, Shen Q, Kim HS, Shin WC, Ahn YM, Park WS, Lee JY, Nam SW.

Oncotarget. 2016 Mar 8;7(10):11412-23. doi: 10.18632/oncotarget.7194.

IF: 6.359

​

2015

 

1. Assessment and Diagnostic Relevance of Novel Serum Biomarkers for Early Decision of ST-elevation Myocardial Infarction

Park HJ*, Noh JH*, Eun JW*, Koh YS, Seo SM, Park WS, Lee JY, Chang K, Seung KB, Kim PJ, Nam SW.

Oncotarget. 2015 May 30;6(15):12970-83.

IF: 6.359

 

2. MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.

Bae HJ*, Jung KH*, Eun JW, Shen Q, Kim HS, Park SJ, Shin WC, Yang HD, Park WS, Lee JY, Nam SW.

J Hepatol. 2015 Mar 25. pii: S0168-8278(15)00202-0. doi: 10.1016/j.jhep.2015.03.019. [Epub ahead of print]

IF: 25.083

 

3. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer.

Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Yang HD, Park M, Park WS, Kang YK, Nam SW.

Oncotarget. 2015 Apr 10;6(10):8089-102

IF: 6.359

 

4. Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.

Eun JW, Bae HJ, Shen Q, Park SJ, Kim HS, Shin WC, Yang HD, Jin CY, You JS, Kang HJ, Kim H, Ahn YM, Park WS, Lee JY, Nam SW.

J Appl Toxicol. 2015 Feb;35(2):152-64. doi: 10.1002/jat.3062. Epub 2014 Sep 18.

IF: 2.982

 

2014

 

1. HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin5-mediated early endosome fusion in gastric cancer.

Park SJ, Kim JK, Bae HJ, Eun JW, Shen Q, Kim HS, Shin WC, Yang HD, Lee EK, You JS, Park WS, Lee JY, Nam SW.

Cancer Lett. 2014 Nov 1;354(1):97-106. doi: 10.1016/j.canlet.2014.07.041. Epub 2014 Aug 8.

IF: 5.621

 

2. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma.

Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim SJ, Park WS, Lee JY, Nam SW.

Oncogene. 2014 May 15;33(20):2557-67. doi: 10.1038/onc.2013.216. Epub 2013 Jun 3.

IF: 8.459

 

3. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT.

Noh JH*, Bae HJ*, Eun JW, Shen Q, Park SJ, Kim HS, Nam B, Shin WC, Lee EK, Lee KB, Jang JJ, Park WS, Lee JY, Nam SW.* Equally contributed

Cancer Res. 2014 Mar 15;74(6):1728-38. doi: 10.1158/0008-5472.CAN-13-2109. Epub 2014 Jan 21.

IF: 9.329

 

4. MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer.

Shen Q, Bae HJ, Eun JW, Kim HS, Park SJ, Shin WC, Lee EK, Park S, Park WS, Lee JY, Nam SW.

Cancer Lett. 2014 Mar 28;344(2):204-11. doi: 10.1016/j.canlet.2013.10.030. Epub 2013 Nov 1.

IF: 5.621

 

5. Oncogenic potential of CK2α and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.

Kim HS*, Chang YG*, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Lee EK, Park S, Ahn YM, Park WS, Lee JY, Nam SW.

* Equally contributed

FEBS J. 2014 Feb;281(3):851-61.

IF: 4.001

 

 

2013

 

1. Characteristic molecular signatures of early exposure to volatile organic compounds in rat liver.

Kim JK*, Eun JW*, Bae HJ, Shen Q, Park SJ, Kim HS, Park S, Ahn YM, Park WS, Lee JY, Nam SW.

* Equally contributed

Biomarkers. 2013 Dec;18(8):706-15. doi: 10.3109/1354750X.2013.847121. Epub 2013 Oct 21.

IF: 2.522

 

2. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.

Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, Park WS, Lee JY, Nam SW.

Cancer Lett. 2013 Mar 14. doi:pii: S0304-3835(13)00226-7.

IF: 5.621

 

3. Characteristic molecular signature for the early detection and prediction of polycyclic aromatic hydrocarbons in rat liver.

Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Kim MG, Chang YG, Shen Q, Kim SJ, Kwon SH, Park WS, Lee JY, Nam SW.

Toxicol Lett. 2013 Jan 10;216(1):1-8. 

IF: 3.262

 

4. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.

Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Shen Q, Park WS, Lee JY, Borlak J, Nam SW.

Hepatology. 2013 Mar;57(3):1055-67.

IF: 11.055

 

5. Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer.

Kim JK, Noh JH, Eun JW, Jung KH, Bae HJ, Shen Q, Kim MG, Chang YG, Kim SJ, Park WS, Lee JY, Borlak J, Nam SW.

Mol Cancer Res. 2013 Jan;11(1):62-73.

IF: 4.380

 

2012

 

1. Characteristic Molecular Signature for Early Detection and Prediction of Persistent Organic Pollutants in Rat Liver.

Kwang Hwa Jung, Jeong Kyu Kim, Min Gyu Kim, Ji Heon Noh, Jung Woo Eun, Hyun Jin Bae, Young Gyoon Chang, Qingyu Shen, Won Sang Par, Jung Young Lee and Suk Woo Nam*

Environ Sci Technol. 2012 Dec 4;46(23):12882-9.

IF: 5.481

 

2. DBC1 does not function as a negative regulator of SIRT1 in liver cancer.

Bae HJ, Chang YG, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Shen Q, Ahn YM, Kwon SH, Park WS, Lee JY, Nam SW.

Oncol Lett. 2012 4: 873-877.

IF: 1.554

 

3. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer.

Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Chang YG, Kim MG, Park WS, Lee JY, Lee SY, Chu IS, Nam SW.

Hepatology. 2012 56(2):644-657

IF: 11.055

 

4. MYC-regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer.

Hunecke D, Spanel R, Länger F, Nam SW, Borlak J.

J Pathol. 2012 May 31. [Epub ahead of print]

IF: 7.429, *Co-corresponding author

 

5. HDAC1 Inactivation Induces Mitotic Defect and Caspase-independent Autophagic Cell Death in Liver Cancer.

Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H, Nam SW.

PLoS One. 2012; 7(3):e34265

IF: 3.234

 

6. HDAC2 Overexpression Confers Oncogenic Potential to Human Lung Cancer Cells by Deregulating Expression of Apoptosis and Cell Cycle Proteins.

Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY, Nam SW.

J Cell Biochem, 2012; 113 (6):2167-77

IF: 3.263

 

2011

 

1. Aberrant Regulation of HDAC2 Mediates Proliferation of Hepatocellular Carcinoma Cells by Deregulating Expression of G1/S Cell Cycle Proteins.

Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park WS, Lee JY, Nam SW. 

PLoS One. 2011;6(11):e28103.

IF: 3.234

 

2. Overexpression of SIRT2 contributes tumor cell growth in hepatocellular carcinomas.

Hong Jian Xie1,*, Kwang Hwa Jung1,* & Suk Woo Nam1.

Mol Cell Toxicol. 2011, Dec. 7:367-374

IF: 1.270

 

3. Molecular signature for early detection and prediction of polycyclic aromatic hydrocarbons in peripheral blood.

Jung KH, Noh JH, Eun JW, Kim JK, Bae HJ, Xie H, Jang JJ, Ryu JC, Park WS, Lee JY, Nam SW. 

Environ Sci Technol. 2011 Jan 1;45(1):300-6.

IF: 5.481

 

4. Identification of characteristic molecular signature for volatile organic compounds in peripheral blood of rat. 

Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, Jang JJ, Ryu JC, Park WS, Lee JY, Nam SW. 

Toxicol Appl Pharmacol. 2011 Jan 15;250(2):162-9

IF: 3.705

 

 

2010

 

 

 

1. Evaluation and application of RNAs derived from laser microdissected specimens using DNA microarray for expression genomics.

Jung Woo Eun, Ho-Sang Jeong, Eun-Jung Kim, Young Min Ahn, Won Sang Park, Jung Young Lee and Suk Woo Nam.

BioChip Journal. 2010 Dec 20. 4(4):322-328.

IF: 1.090

 

2. Decreased expression of TFF2 and gastric carcinogenesis. 

Kwang Hwa Jung,*, Pum Joon Kim,*, Jeong Kyu Kim, Ji Heon Noh, Hyun Jin Bae, Jung Woo Eun, Hong Jian Xie, Jin Mei Shan, Win Yin Ping, Won Sang Park, Jung Young Lee & Suk Woo Nam. 

Mol Cell Toxicol. 2010 Sep; 6:261-269

IF: 1.270

 

3. Decreased expression of Annexin A10 in gastric cancer and its overexpression in tumor cell growth suppression.

Kim JK, Kim PJ, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, Shan JM, Ping WY, Park WS, Lee JY, Nam SW. 

Oncol Rep. 2010 Sep;24(3):607-12.

IF: 2.301

 

4. Targeted-disruption of Nemo-Like Kinase Inhibits Tumor Cell Growth by Simultaneous Suppression of Cyclin D1 and CDK2 in Human Hepatocellular Carcinoma. 

Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Park WS, Lee JY, Nam SW. 

J Cell Biochem. 2010 Jun 1;110(3):687-96.

IF: 3.263

 

5. Identification of post-generation effect of 3, 4- methylenedioxymethamphetamine on the mouse brain by large-scale gene expression analysis. 

Eun JW, Kwack SJ, Noh JH, Jung KH, Kim JK, Bae HJ, Xie H, Ryu JC, Ahn YM, Park WS, Lee JY, Rhee GS, Nam SW. 

Toxicol Lett. 2010 May 19;195(1):60-7. Epub 2010 Feb 24.

IF: 3.262